Definitive, Late Phase Trials
Phase 3 Treatment Trials in Early Stage Non-Small Cell Lung Cancer Will Assess the Clinical Benefit of Bevacizumab as Part of Adjuvant Therapy and Surgical Resection Techniques
Two definitive phase 3 studies involving early stage non-small cell lung cancer (NSCLC) were activated in June 2007. The results of these two phase 3 trials may have profound impacts on the management and quality of life of patients with early stage lung cancer.
Adjuvant Treatment for Resected Lung Cancer
ECOG is leading a trial, E1505, for patients with early stage NSCLC to test if the addition of bevacizumab (angiogenesis inhibition) to standard chemotherapy will improve survival in patients undergoing surgery with curative intent. This study is based on the results of another CTEP-sponsored phase 3 study in patients with advanced non-squamous NSCLC (E4599) that showed that adding bevacizumab to standard chemotherapy for patients with NSCLC provides a statistically and clinically significant survival advantage with tolerable toxicity.
Comparing Surgical Treatment for Small NSCLC Tumors
The CALGB is conducting a phase 3 study, CALGB-140503, which will compare two types of surgical resection (standard lobectomy versus sublobar resection) for small (≤ 2 cm) peripheral tumors.
Jeffrey S. Abrams, M.D., has led the Cancer Therapy Evaluation Program (CTEP) since June 2007. Dr. Abrams came to CTEP in 1993 when he joined as a clinical research scientist to oversee the breast cancer treatment trials portfolio and participate in clinical trials at the NIH Clinical Center and the National Naval Medical Center. More…